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Pseudomonas aeruginosa Bacteremia in Children Over Ten 
Consecutive Years: Analysis of Clinical Characteristics, Risk 
Factors of Multi-drug Resistance and Clinical Outcomes
This study aimed to evaluate the clinical profiles, antibiotic susceptibility, risk factors of 
multi-drug resistance (MDR) and outcomes of P. aeruginosa bacteremia in children by 
retrospective methods at a tertiary teaching children’s hospital in Seoul, Korea during 
2000-2009. A total of 62 episodes were evaluated and 59 patients (95.2%) had underlying 
diseases. Multivariate analysis demonstrated that an intensive care unit (ICU) stay within 
the previous one month was the only independent risk factor for MDR P. aeruginosa 
bacteremia (odds ratio [OR], 6.8; 95% confidence interval [CI], 1.3-35.8, P = 0.023). The 
overall fatality rate associated with P. aeruginosa bacteremia was 14.5% (9 of 62). The 
fatality rate in patients with MDR P. aeruginosa was 57.1%, compared with 9.1% in non-
MDR patients (OR 13.3; 95% CI 2.3-77.2, P = 0.006). However, the presence of 
respiratory difficulty was the only independent risk factor for overall fatality associated 
with P. aeruginosa bacteremia according to multivariate analysis (OR 51.0; 95% CI 7.0-
369.0, P < 0.001). A previous ICU stay and presentation with respiratory difficulty were 
associated with acquisition of MDR P. aeruginosa and a higher fatality rate, respectively. 
Future efforts should focus on the prevention and treatment of P. aeruginosa bacteremia 
in high-risk children. 
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INTRODUCTION
Pseudomonas aeruginosa, an aerobic Gram-negative organism 
that is commonly discovered in soil, water, and plants, rarely 
causes illness in healthy people (1). However, P. aeruginosa sep-
sis often occurs in patients with burns, malignancies or immu-
nodeficiency or in preterm infants (1). Most of these infections 
are nosocomially acquired (1). P. aeruginosa is a virulent organ-
ism that is susceptible to a limited number of antibiotic agents 
including antipseudomonal penicillins and cephalosporins, car-
bapenems, fluoroquinolones and ciprofloxacin (2-4). Despite 
recent improvements in therapy, P. aeruginosa bacteremia re-
mains fatal in more than 20% of cases (5). In a recent large mul-
ticenter study of all age groups, P. aeruginosa bloodstream in-
fection (BSI) was associated with crude mortality rates of 39% 
in all patients and 48% in intensive care unit patients (6).
  The outcome of P. aeruginosa bacteremia has been shown to 
be related to microbial (7, 8) and host factors (9-11) and treat-
ment (10-12). Understanding these factors may provide an im-
provement in treatment outcome. 
  Despite an abundance of studies on the risk factors for multi-
drug resistance (MDR) and mortality of P. aeruginosa bactere-
mia, relatively few studies on P. aeruginosa bacteremia in chil-
dren have been reported in recent years (13-16). We conducted 
an analysis of 62 pediatric patients with P. aeruginosa bactere-
mia at a tertiary care children’s hospital during a recent ten-year 
period. We investigated the risk factors for acquisition of MDR 
P. aeruginosa and the mortality rate associated with P. aerugi-
nosa bacteremia as well as its clinical characteristics and antibi-
otic susceptibility.  
MATERIALS AND METHODS
This was a retrospective analysis conducted at the Seoul Nation-
al University Children’s Hospital (SNUCH), a 300-bed tertiary 
care university hospital and pediatric referral center located in 
Seoul, Korea. 
Study population
From January 2000 through December 2009, we studied pediat-
ric patients younger than 18 yr of age who had at least one posi-
tive blood culture for P. aeruginosa during hospitalization. The Yang MA, et al.  •  Pseudomonas aeruginosa Bacteremia in Children
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collected data included age, gender, type of acquisition, under-
lying disease, previous antimicrobial therapy, neutropenia, use 
of immunosuppressive treatment, prior surgery, use of vascular 
or urinary catheters, invasive procedures during the prior 72 hr, 
use of a mechanical ventilator within the previous month, pres-
ence of initial septic shock, respiratory difficulty, renal insuffi-
ciency, hepatic dysfunction, antibiotic susceptibility, MDR, and 
treatment outcome. 
Definitions
The presence of P. aeruginosa bacteremia was defined as the 
isolation of P. aeruginosa in a blood culture (12). Only the first P. 
aeruginosa isolate, during a single clinical event, was included 
in the analysis. However, it was considered as a non-related, in-
dependent episode, if more than one episode was occurred with 
more than a two-week interval in a same patient who had been 
properly treated and clinically cured (17).
  Septic shock was defined as sepsis and hypotension (18) (sys-
tolic blood pressure [BP] < 70 mmHg in infant; < 70 + [2 × age in 
year] after one year of age) or need for a vasopressor to maintain 
blood pressure (12). The primary focus of infection was defined 
as a culture-positive site and/or a clinically evident site of infec-
tion concomitant with bacteremia (19). Diagnosis of catheter-
related bacteremia was defined as P. aeruginosa bacteremia in 
a patient who had an intravascular device and more than one 
positive blood culture result from the peripheral vein, clinical 
manifestations of infection (e.g., fever, chills, and/or hypoten-
sion), and no apparent source for BSI (with the exception of the 
catheter). One of the following should be present: a positive re-
sult of semiquantitative (> 15 colony-forming unit per catheter 
segment) or differential time to positivity (growth in a culture of 
blood obtained through a catheter hub detected via an auto-
mated blood culture system at least 2 hr earlier than a culture of 
simultaneously drawn peripheral blood of equal volume) (20). 
Prior steroid use was defined as at least 2 mg/kg/day or ≥ 20 mg 
of prednisone daily for at least ten of the 30 days before the di-
agnosis of bacteremia. Patients who had malignant disease, pre-
mature babies, and patients receiving steroid therapy were clas-
sified as immunocompromised (19). 
  The empirical antimicrobial therapy was considered appro-
priate if the causative organism was susceptible to at least one 
of the prescribed antimicrobials according to an in vitro test with-
in 24 hr after blood culture sampling (12, 19). 
Microbiology and antibiotic susceptibility
P. aeruginosa isolates obtained from the blood of patients at the 
SNUCH during the study period from January 2000 through 
December 2009 were collected and stored at -70°C. Species iden-
tification was carried out using VITEK-GNI cards (BioMerieux, 
Hazelwood, MO, USA) from 2000 to 2006 and was performed 
using the VITEK II system (BioMerieux) or Microscan system 
(MicroScan
® WalkAway 96 plus system, Siemens Healthcare 
Diagnostics Inc., West Sacramento, CA, USA) after 2006. 
  Antibiotic susceptibility testing was performed using the disk 
diffusion method recommended by the CLSI guidelines (21) or 
the automatically calculated minimal inhibitory concentration 
(MIC) method of VITEK or a Microscan system. The tested an-
tibiotics included amikacin, aztreonam, cefepime, ceftazidime, 
ciprofloxacin, gentamicin, imipenem, piperacillin, piperacillin/
tazobactam, and tobramycin. Intermediate susceptibility to an 
antibiotic was considered as resistance, in correspondence with 
clinical practice. MDR was defined as a lack of susceptibility to 
three or more of the following antibiotics: 1) ciprofloxacin; 2) 
imipenem; 3) gentamicin, tobramycin, or amikacin; 4) ceftazi-
dime or cefepime; and 5) piperacillin or piperacillin-tazobac-
tam (22). 
Statistical analysis 
Potential risk factors for MDR P. aeruginosa bacteremia and 
mortality were identified using univariate analysis, and Fisher’s 
exact test was used for categorical variables. Variables for which 
the P value was < 0.05 in univariate analysis were included in a 
logistic regression model for multivariable analysis using a back-
ward-Wald selection process. A P value < 0.05 was considered 
statistically significant. A statistical package (SPSS, version 17.0, 
SPSS Inc, Chicago, IL, USA) was used for all analyses. 
 
Ethics statement
This study was approved by the institutional review board of the 
Seoul National University Hospital (IRB registration number H- 
1007-151-324). Informed consent was exempted by the board.
RESULTS
Epidemiology and demographic characteristics
During the period from January 2000 to December 2009, a total 
of 75 patients with P. aeruginosa bacteremia were identified at 
the SNUCH. On average, 7.5 episodes of P. aeruginosa bactere-
mia occurred in one year with a range of 1-15 cases per year. The 
mean incidence rate (± standard deviation; SD) was 0.09 (± 0.05) 
episodes/1,000 patient-admission days per year. Among the 75 
cases of P. aeruginosa bacteremia, medical records were unavail-
able for 13 (17.3%) patients, which were excluded from clinical 
analysis and as a result, a total of 62 episodes was analyzed in 
this study.
  The mean (± SD) age of the patients was 6.5 (± 5.5) yr old 
(range; 0-17 yr old), and 40 (64.5%) patients were male (Table 1). 
P. aeruginosa bacteremia occurred in a mean of 29.5 hospital-
days. 
  Fifty-nine (95.2%) of 62 patients had underlying disease. The 
most common underlying diseases were hematological and on-
cological disease; 58.1% (36/62) of the patients had neutrope-Yang MA, et al.  •  Pseudomonas aeruginosa Bacteremia in Children
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nia with an absolute neutrophil count < 500 cells/μL at the on-
set of bacteremia. Three patients (4.8%) had no underlying dis-
ease, and all of these patients were younger than one year of age. 
The initial diagnoses in these three were pneumonia with pleural 
effusion, severe skin infection, and bacteremia without focus.
  At the onset of bacteremia, 40 patients (64.5%) had infection 
foci. The most common infection site was the lung (22.6%; 14/ 
62), followed by skin and soft tissue (16.1%; 10/62) and central 
catheter-related infection (11.3%; 7/62). Primary sites of infec-
tion could not be elucidated in 35.5% (22/62) cases.
Antimicrobial susceptibility 
Of the 62 P. aeruginosa isolates, the resistance rates for the anti-
biotics were as follows; 24.2% for aztreonam, 16.1% for imipen-
em, 14.5% for gentamicin, 12.9% for piperacillin and piperacil-
lin/tazobactam, and 11.3% for cefepime and ceftazidime, respec-
tively. 
  Seven isolates (11.3%) showed MDR phenotypes, five of which 
were identified in 2003; remaining two isolates were identified 
in each year of 2005 and 2008, separately. For the MDR pheno-
types, there was no overlapping patient. P. aeruginosa isolates 
with cefepime, piperacillin and piperacillin/tazobactam resis-
tance showed MDR phenotypes substantially. Pan-drug resis-
tance for P. aeruginosa was not yet identified in this study. Only 
one (1.6%) isolate was resistant against amikacin. All of the iso-
lates tested were susceptible to ciprofloxacin.
Risk factors for MDR P. aeruginosa bacteremia 
The variables considered as possible risk factors for acquisition 
of MDR-P. aeruginosa are shown in Table 2. In the univariate 
analysis, MDR-P. aeruginosa cases were more frequently asso-
ciated with previous extended-spectrum cephalosporin use 
within one month (OR, 6.0; 95% CI, 1.2-31.1), an intensive care 
unit (ICU) stay (OR, 6.8; 95% CI, 1.3-35.8), and a long hospital 
stay (> 30 days) (OR, 5.3; 95% CI, 1.0-27.4). 
  An ICU stay within the previous one month was the only sta-
tistically-significant risk factor for MDR acquisition in the mul-
tivariate analysis, adjusted for age and gender in addition to the 
variables with P < 0.05 in the univariate analysis (adjusted OR, 
6.8; 95% CI, 1.3-35.8, P = 0.023)
Clinical outcomes of P. aeruginosa bacteremia 
The overall case fatality associated with P. aeruginosa bactere-
mia was 14.5% (9 of 62). The fatality rate of the MDR-P. aerugi-
nosa group was 57.1% (4/7) compared with 9.1% (5/55) in the 
non-MDR group (OR, 13.3; 95% CI, 2.3-77.2, P = 0.006). 
  A higher fatality rate was observed in the cases with the fol-
lowing factors by the univariate analysis; pulmonary infection, 
presentation with septic shock, respiratory difficulty, renal in-
sufficiency, and antibiogram of MDR phenotype (Table 3). Pres-
Table 1. The characteristics of 62 patients with P. aeruginosa bacteremia
Characteristics No. (%)
Mean ± standard deviation age (yr) 6.47 ± 5.51
Gender
   Male
   Female
 
40 (64.5)
22 (35.5)
Underlying disease
   Hematological or oncological disease*
   Cardiovascular disease
   Nephrological or urological disease
   Neurological disease
   Hepatobiliary disease 
   Congenital immune deficiency 
   Others
59 (95.2)
39 (62.9)
5 (8.1)
5 (8.1)
4 (6.5)
2 (3.2)
2 (3.2)
2 (3.2)
Primary site of infection 
   Lung
   Skin and soft tissue
   Catheter-related
   Urinary tract 
   Gastro-intestinal 
   Ear
   Bacteremia without focus 
14 (22.6)
10 (16.1)
   7 (11.3))
4 (6.5)
4 (6.5)
1 (1.6)
22 (35.5)
*These included leukemia (25.8%), solid tumor (24.2%), lymphoma (4.8%), hemo-
phagocytic lymphoproliferative histiocytosis (4.8%), and aplastic anemia (3.2%).
Table 2. Risk factors for MDR P. aeruginosa bacteremia in 62 patients from SNUCH over a ten-year period 
Variables
MDR  
(7 patients),  
No. (%)
Non-MDR  
(55 patients),  
No. (%)
Unadjusted OR (95% CI) P value* Adjusted OR (95% CI)
Demographic characters
   Mean ± SD age (yr)
   Gender, male
 
3.8 ± 5.5
 5 (71.4)
 
6.8 ± 5.5
   35 (63.6)
 
1.13 (0.9-1.4)
1.43 (0.3-8.1)
 
0.186
0.686
 
Use of any antibiotics within previous one month
   Extended-spectrum cephalosporins
   Carbapenem 
7 (100)
 4 (57.1)
 3 (42.9)
   45 (81.8)
   10 (18.2)
     7 (12.7)
-
    6.0 (1.2-31.1)
  5.14 (1.0-28.0)
0.999
0.033
0.058
Long hospital stay (> 30 days)  4 (57.1) 11 (20)   5.33 (1.0-27.4) 0.045
Care in an intensive care unit within previous one month  4 (57.1)      9 (16.4)   6.82 (1.3-35.8) 0.023 6.82 (1.3-35.8)
Ventilator use in previous one month  3 (42.9)      8 (14.5)   4.41 (0.8-23.5) 0.083
Presence of an indwelling central venous catheter 7 (100)    24 (43.6) - 0.998
Presence of an indwelling urinary catheter  1 (14.3)    2 (3.6)   4.42 (0.4-56.3) 0.253
Immunocompromised
†  3 (42.9)    41 (74.5) 0.26 (0.1-1.3) 0.098
*Variables with P < 0.05 on univariate analysis were included in the multivariate analysis; 
†Patients who had malignant disease, premature birth, or who had received steroid 
therapy (Reference No. 19).Yang MA, et al.  •  Pseudomonas aeruginosa Bacteremia in Children
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ence of respiratory difficulty was revealed to be an independent 
risk factor for higher all-cause fatality according to the multivar-
iate logistic regression analysis adjusted for age, gender and the 
variables with P < 0.05 in the univariate analysis (OR, 51.0; 95% 
CI, 7.0-369.0, P < 0.001). 
  Nine (14.5%) patients were treated with inappropriate initial 
antimicrobial regimens for P. aeruginosa bacteremia; six (66.6%) 
of these patients did not receive any antibiotics directed against 
P. aeruginosa (e.g. anti-pseudomonal beta-lactams) as an initial 
empirical treatment. Three (33.3%) of the nine patients were ini-
tially treated with antibiotics that have known anti-pseudomonal 
activity, for which the isolates were actually resistant based on 
the in vitro susceptibility test. The fatality rate of the patients who 
were treated with appropriate initial antimicrobial regimens for 
P. aeruginosa bacteremia was 15% (8/53) and the fatality rate 
among the patients with inappropriate initial antimicrobial reg-
imens was 11.1% (1/9); a statistically significant difference among 
these two groups was not observed (P = 0.755 by Fisher’s exact 
test). 
DISCUSSION 
The objective of the present retrospective study was to evaluate 
the clinical patterns, antibiotic sensitivity, independent risk fac-
tors for MDR and treatment outcomes of P. aeruginosa bactere-
mia in children. We found that fifty-nine (95.2%) of 62 patients 
had underlying disease, seven isolates (11.3%) showed MDR 
phenotypes, and overall case fatality was 14.5% (9 of 62). We also 
found that ICU stay within the previous one month was indepen-
dently associated with the development of MDR P. aeruginosa 
bacteremia, and presentation with respiratory difficulty was an 
independent risk factor for all-cause fatality due to P. aerugino-
sa bacteremia. Previous investigations have already described 
risk factors of an MDR phenotype in P. aeruginosa infection. Cao 
et al. (4) demonstrated that the use of imipenem or meropen-
em and mechanical ventilation were independent risk factors 
for MDR P. aeruginosa infections. Johnson et al. (22) document-
ed that previous transplantation, hospital-acquired BSI and ICU 
admission in the year before MDR P. aeruginosa BSI were inde-
pendent risk factors. Gulay et al. (23) showed that the major risk 
factors for infection or colonization with MDR P. aeruginosa were 
prolonged stay in the ICU, previous and lengthy imipenem us-
age, and mechanical ventilation. To our knowledge, our study 
provides the first data revealing the risk factors of an MDR P. ae-
ruginosa infections among pediatric groups based on the 10 yr 
observation, in which previous ICU stay was found to be a risk 
factor of MDR P. aeruginosa infection. It may be hypothesized 
that colonization of P. aeruginosa in the ICU can cause infection 
and may be a risk factor for MDR P. aeruginosa infection. 
  Recently, resistance to antimicrobial agents of P. aeruginosa 
has become a more serious clinical problem (3, 24, 25). More-
over, prevalence of MDR phenotype is increasing among P. ae-
ruginosa in adult patients (26, 27). However, we were unable to 
demonstrate an increased imipenem-resistance or MDR phe-
notypes of P. aeruginosa bacteremia during the study period. 
This phenomenon might be associated with the small number 
of cases in this study. Furthermore, all isolates were susceptible 
to ciprofloxacin, which differs from results from another study 
Table 3. Risk factors for fatal outcomes associated with P. aeruginosa bacteremia 
Variables Died  
(9 patients), No. (%)
Recovered  
(53 patients), No. (%) Unadjusted OR (95% CI) P value Adjusted OR  
(95% CI)*
Demographic characters
   Mean ± SD age (yr)
   Gender, male
 
4.08 ± 4.61
6 (66.7)
 
6.88 ± 5.59
34 (64.2)
 
1.114 (1.0-1.3)
0.895 (0.2-4.0)
 
0.171
0.884
Source of infection
   Lung
   Catheter-related
   Urinary tract
   Skin and soft tissue
   Gastrointestinal
   Ear
   Bacteremia without focus 
 
6 (66.7)
1 (11.1)
0
1 (11.1)
0
0
1 (11.1)
 
   8 (15.1)
   6 (11.3)
 4 (7.5)
9 (17)
 4 (7.5)
 1 (1.9)
 21 (39.6)
 
11.25 (2.3-54.4)
1.021 (0.1-9.6)
 
1.636 (0.2-14.8)
 
 
5.25 (0.6-45.1)
 
0.003
0.985
0.999
0.661
0.999
1
0.131
Initial organ dysfunction
   Septic shock
   Renal insufficiency
†
   Hepatic dysfunction
‡
   Neurological dysfunction
§
   Respiratory difficulty
ll
 
6 (66.7)
2 (22.2)
3 (33.3)
2 (22.2)
6 (66.7)
 
   8 (15.1)
 1 (1.9)
   8 (15.1)
 4 (7.5)
 2 (3.8)
 
11.25 (2.3-54.4)
14.857 (1.2-185.9)
2.812 (0.6-13.6)
3.5 (0.5-22.8)
51 (7.0-369.0)
 
0.003
0.036
0.199
0.19
< 0.001
 
 
 
 
 
51 (7.0-369.0)
First isolation was MDRP 4 (44.4)  3 (5.7) 13.333 (2.3-77.2) 0.004
Immunocompromised  6 (66.7)  38 (71.7) 0.789 ( 0.2-3.6) 0.759
Inappropriate antimicrobial therapy 1 (11.1)    8 (15.1) 0.703 (0.1-6.4) 0.755
*Variables with P < 0.05 on univariate analysis were included in the multivariable analysis; 
†A serum creatinine level of > 2.0 mg/dL or a requirement for dialysis (Reference No. 
19); 
‡A serum bilirubin concentration of > 2.5 mg/dL, increased aspartate aminotransferase level or alanine aminotransferase level more than twice the normal level (Reference 
No. 19); 
§Change in con  sciousness level (Reference No. 19); 
llA partial arterial O2 pressure of < 60 mmHg, a partial arterial CO2 pressure of > 50 mmHg, or a need for ventilator 
assistance (Reference No. 19).Yang MA, et al.  •  Pseudomonas aeruginosa Bacteremia in Children
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(28). Recently the resistance rate for quinolone among E. coli 
and K. pneumoniae blood isolates obtained from children in 
our institute was increasing accompanying with an increment 
of quinolone usuage (unpublished data). As a result, continu-
ous monitoring should be manditory for increasing trends of 
MDR phenotypes or quinolone resistance among P. aeruginosa 
isolates in pediatric hospitals. 
  Infections caused by MDR P. aeruginosa are difficult to treat 
(4). Our results show the case fatality for MDR group to be as 
high as 50% and higher than that in the non-MDR group, even 
though some studies have suggested that MDR phenotype is 
not a predictor for fatality with P. aeruginosa (4, 22). This fatality 
rate was consistent with the result of an earlier study which re-
ported that the odds of death in patients with MDR P. aeruginosa 
bacteremia was 3.9 (95% CI, 1.42-10.78, P = 0.002) times higher 
than that for patients with non-MDR P. aeruginosa (16). 
  The fatality rate associated with P. aeruginosa bacteremia is 
higher than those of all other bacteremia in the hospital settings. 
Thus, appropriate initial antimicrobial therapy is of particular 
importance in these cases. There are several studies emphasiz-
ing the importance of appropriate initial antimicrobial treatment 
(11, 12, 29). Kang et al. (12) emphasized that delayed effective 
antimicrobial therapy for P. aeruginosa bacteremia, presentation 
with septic shock, pneumonia and increasing APACHE II score 
tended to be related to higher mortality. However, in another 
study, inactive empiric antibiotic therapy was not an indepen-
dent predictor of mortality with MDR P. aeruginosa infection, 
but the authors postulated a small number of patients who re-
ceived inappropriate empiric therapy (4.6%; 23/503) as the cause 
(22). In the current study, the initial appropriateness of antibiot-
ics was not a predictor of fatality like a previous study (22). This 
result was probably due to the small number (14.5%) of the pa-
tients who had initially received inappropriate empirical thera-
py and who then later received the appropriate antibiotics. 
  In a pediatric study, Grisaru-Soen et al. (14) demonstrated 
that underlying disease was the only factor correlated with mor-
tality according to multiple regression analysis. In our study, 
most of the P. aeruginosa bacteremia cases occurred to the pa-
tients with underlying disease, but underlying disease was not 
an independent risk factor (data was not shown). In our study, 
the presence of respiratory difficulty was the only independent 
risk factor related to overall fatality. 
  This study has several limitations. First, it was retrospective 
and performed at a single health-care center. Therefore, the re-
sults are not representative of all pediatric patients in Korea. 
Second, we did not conduct an analysis of the genotypes of the 
P. aeruginosa isolates and did not elucidate clustered occurrence 
of MDR phenotypes in 2003. Third, for the outcome analysis, 
the formal severity of the illness scores could not be calculated 
due to the retrospective nature of this study and to the absence 
of certain data in the medical records. 
  However, this study has some advantages. Our hospital is a 
referral institution and a university-affiliated tertiary hospital 
with relatively many pediatric patients diagnosed with P. aeru-
ginosa bacteremia. In addition, this study included for invasive 
P. aeruginosa isolates obtained over a consecutive 10 yr.
  In conclusion, our study revealed that a previous ICU stay was 
associated with acquisition of MDR P. aeruginosa and presen-
tation with respiratory difficulty was independent predictors of 
fatal outcomes among pediatric patients with P. aeruginosa bac-
teremia. P. aeruginosa bacteremia has become a major concern 
not only for adults but also for children with underlying disease 
who are at high risk for health care-associated infection. Con-
tinuous monitoring is required for early detection of increment 
of MDR or PDR-phenotypes among P. aeruginosa isolates and 
for timely management of patients with probably higher fatality 
rate. Additionally, future efforts should be concentrated on the 
prevention and treatment of P. aeruginosa bacteremia in high-
risk children.  
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Pseudomonas aeruginosa Bacteremia in Children Over Ten Consecutive Years: 
Analysis of Clinical Characteristics, Risk Factors of Multi-drug Resistance and 
Clinical Outcomes
Mi Ae Yang, Jina Lee, Eun Hwa Choi, and Hoan Jong Lee
This study aimed to evaluate the clinical profiles, antibiotic susceptibility, risk factors of multi-drug resistance (MDR) and outcomes 
of P. aeruginosa bacteremia in children. We retrospectively reviewed medical records of pediatric patients with P. aeruginosa 
bacteremia at a tertiary children’s hospital in Seoul, Korea from January 2000 to December 2009. A total of 62 episodes were 
evaluated. An intensive care unit (ICU) stay within the previous one month was the only independent risk factor for MDR P. 
aeruginosa bacteremia. The overall fatality rate associated with P. aeruginosa bacteremia was 14.5%. The fatality rate in patients 
with MDR P. aeruginosa was 57.1%, compared with 9.1% in non-MDR patients. However, the presence of respiratory difficulty 
was the only independent risk factor for overall fatality associated with P. aeruginosa bacteremia. A previous ICU stay and 
presentation with respiratory difficulty were associated with acquisition of MDR P. aeruginosa and a higher fatality rate, respectively.